System Code: CMF-DOE-0011

Classification: Closed-Loop Multi-Axis Therapeutic Control System

Primary Objective: Minimize chaos load, maximize coherence, and converge the patient toward Stability

I. CONTROL OBJECTIVE

1.1 Governing Principle

The engine controls treatment by continuously updating:

$U(t) = \begin{bmatrix} u_1(t) \\ u_2(t) \\ u_3(t) \\ u_4(t) \\ u_5(t) \\ u_6(t) \end{bmatrix}$

Where:

1.2 Desired State

The target is:

$\Psi(t) \rightarrow \Psi_{\text{stable}}$

with the following conditions:

$V(t) \approx H(t), \qquad \mathbf{C}(t)\uparrow, \qquad \mathbf{\Omega}(t)\downarrow$

Meaning:

• Vertical Axis stabilized
• Horizontal Axis productive but not destabilizing
• Six Currents aligned
• Chaos field suppressed

II. STATE SPACE OF THE ENGINE

2.1 Patient State Vector

$x(t) = \begin{bmatrix} R(t) \\ C_o(t) \\ S_T(t) \\ A(t) \\ E(t) \\ B(t) \\ M(t) \\ T(t) \\ \Phi(t) \\ \Omega_{cyto}(t) \\ \Omega_{org}(t) \\ \Omega_{imm}(t) \end{bmatrix}$

2.2 Observed Biomarker Vector

$y(t) = \begin{bmatrix} \text{HRV} \\ \text{IL6} \\ \text{TNF}\alpha \\ \text{CRP} \\ \text{Cortisol} \\ \text{Melatonin phase} \\ \text{EEG entropy} \\ \text{Gamma coherence} \\ \text{ATP / NAD}^+ \\ \text{BDNF} \\ \text{DMN activity} \\ \text{Sleep regularity} \end{bmatrix}$

These are the practical inputs for estimating latent CMF variables.

III. CORE OPTIMIZATION FORMULATION

3.1 Objective Function

The engine minimizes total system instability:

$J(U) = w_1\|\Psi_{\text{stable}} - \Psi(t)\|^2 + w_2\|\mathbf{\Omega}(t)\|^2 + w_3\|V(t)-H(t)\|^2 + w_4\|U(t)\|^2 + w_5\|\Delta U(t)\|^2$

3.2 Interpretation of Terms

This keeps the system effective but conservative.

IV. ENGINE ARCHITECTURE

4.1 Closed-Loop Control Cycle

Biomarkers → State Estimation → CMF State Classification → Optimization Solver → U(t) Update → Dosing Recommendation → Re-measurement

4.2 Core Modules

V. STATE ESTIMATION LAYER

5.1 Latent Variable Estimation

Because CMF variables are not directly observed, estimate them as:

$\hat{x}(t) = \mathcal{G}(y(t))$

Where $\mathcal{G}$ may be:

• Bayesian filter
• Extended Kalman filter
• particle filter
• learned digital twin estimator

5.2 Example Biomarker-to-State Mapping

VI. STATE-CLASSIFICATION LOGIC

6.1 CMF State Classifier

$\hat{S}(t) = \mathcal{H}(\hat{x}(t))$

Where $\hat{S}(t) \in \{\text{Chaos, Suffering, Return, Acceptance, Death, Echo, Stability}\}$

6.2 Therapeutic Priority by State

VII. CONTROL LAW FOR U(t)

7.1 Base Feedback Control

$U(t) = U_{\text{base}} + K\big(x_{\text{target}} - \hat{x}(t)\big)$

Where:

• $U_{\text{base}}$ = baseline therapeutic scaffold
• K = control gain matrix
• $x_{\text{target}}$ = target Stability vector

7.2 Expanded State-Specific Control

VIII. COMPONENT-SPECIFIC ADJUSTMENT RULES

8.1 Anti-inflammatory Control u_1

$u_1(t) = k_{11}\Omega_{imm}(t) + k_{12}I(t) - k_{13}S_T(t)$

Increase u_1 when:

• IL-6 / TNF-α / CRP high
• vagal control low
• self-tolerance reduced

8.2 Neurostabilization Control $u_2$

$u_2(t) = k_{21}(1-R) + k_{22}(1-C_o) + k_{23}E$

Increase $u_2$ when:

• resonance collapsed
• coherence low
• emotional flooding high

8.3 Metabolic Support $u_3$

$u_3(t) = k_{31}(1-M) + k_{32}\Omega_{imm}$

Increase u_3 when:

• ATP/NAD^+ low
• immune drain high

8.4 Chronotherapy Control $u_4$

$u_4(t) = k_{41}(1-T) + k_{42}\text{phase error}$

Increase $u_4$ when:

• circadian rhythm off-phase
• sleep irregularity high
• cortisol rhythm flattened

8.5 Plasticity Modulation $u_5$

$u_5(t) = k_{51}(1-\Phi) + k_{52}\Omega_{org} - k_{53}\Omega_{cyto}$

Interpretation:

• raise $u_5$ when adaptive transformation is too low
• restrain $u_5$ if cytogenetic chaos is high and the system is unstable

8.6 Vagal / Autonomic Control $u_6$

$u_6(t) = k_{61}(1-B) + k_{62}(1-\text{HRV}) + k_{63}\Omega_{imm}$

Increase $u_6$ when:

• embodiment collapses
• HRV low
• immune chaos high

IX. SAFETY GOVERNOR

9.1 Hard Constraints

$U_{\min} \le U(t) \le U_{\max}$

$|\Delta U(t)| \le \Delta U_{\max}$

9.2 Risk Penalties

The engine must suppress recommendations if estimated risk exceeds threshold:

$\mathcal{R}(t) = r_1(\text{oversedation}) + r_2(\text{overplasticity}) + r_3(\text{immune suppression}) + r_4(\text{circadian destabilization}) + r_5(\text{metabolic overload})$

If:

$\mathcal{R}(t) > \mathcal{R}_{\max}$

then the optimizer shifts to a safety-constrained regime.

X. MODEL PREDICTIVE CONTROL LAYER

10.1 Predictive Horizon

Use a finite horizon N to optimize over future steps:

$\min_{U_{t:t+N}} \sum_{\tau=t}^{t+N} J\big(x(\tau), U(\tau)\big)$

subject to:

$x(\tau+1) = F\big(x(\tau), U(\tau)\big)$

This allows the engine to avoid short-term improvements that produce later destabilization.

10.2 Why MPC Fits CMF

Because CMF states are path-dependent:

• lowering Chaos too abruptly may push into Suffering
• increasing plasticity too early may worsen Organized Chaos
• correcting Time too late may impair Transformation

MPC handles these tradeoffs.

XI. STATE-SPECIFIC OPTIMIZATION PROFILES

11.1 Chaos Profile

Goal:

$\Omega_{imm}\downarrow,\; R\uparrow,\; C_o\uparrow$

Priority vector:

$U_{\text{chaos}} = [u_1 \uparrow,\; u_2 \uparrow,\; u_3 \uparrow,\; u_4 \rightarrow,\; u_5 \downarrow/\text{guarded},\; u_6 \uparrow]$

Meaning:

• strong anti-inflammatory
• strong neurostabilization
• metabolic rescue
• guarded plasticity
• autonomic stabilization

11.2 Suffering Profile

Goal:

$A\uparrow,\; \Phi\uparrow,\; E_{\text{loop}}\downarrow$

Priority vector:

$U_{\text{suffering}} = [u_1 \rightarrow,\; u_2 \rightarrow,\; u_3 \uparrow,\; u_4 \uparrow,\; u_5 \uparrow,\; u_6 \uparrow]$

Meaning:

• less acute suppression
• more flexibility, timing repair, and re-patterning

11.3 Return Profile

Goal:

$V \approx H,\; \mathbf{C}\uparrow$

Priority vector:

$U_{\text{return}} = [u_1 \downarrow,\; u_2 \rightarrow,\; u_3 \rightarrow,\; u_4 \uparrow,\; u_5 \uparrow,\; u_6 \rightarrow]$

11.4 Stability Profile

Goal:

$\Psi \rightarrow \Psi_{\text{stable}}, \quad U(t)\rightarrow U_{\min}$

Priority:

• maintain with lowest effective burden
• minimize oscillation
• preserve resilience margin

XII. DRUG-MAPPING LAYER

12.1 Therapeutic Domain Mapping

This engine does not require naming a single fixed drug. It controls therapeutic domains:

For a candidate such as SYNAPTARA-7™, the engine can adjust relative component emphasis rather than treating each term as a separate drug.

XIII. RESPONSE LEARNING

13.1 Adaptive Gain Updating

The control gains should update with patient response:

$K_{t+1} = K_t + \eta \nabla \mathcal{L}$

Where:

• $K_t$ = current gain matrix
• $\eta$ = learning rate
• $\nabla \mathcal{L}$ = gradient of prediction error or outcome loss

This converts the system into a patient-specific digital twin.

XIV. CLINICAL DASHBOARD OUTPUT

14.1 Engine Output Table

14.2 Example Decision Logic

XV. MASTER EQUATION OF THE ENGINE

$\boxed{ U^*(t) = \arg\min_{U} \left[ w_1\|\Psi_{\text{stable}}-\Psi(t)\|^2 + w_2\|\mathbf{\Omega}(t)\|^2 + w_3\|V(t)-H(t)\|^2 + w_4\|U(t)\|^2 + w_5\|\Delta U(t)\|^2 \right] }$

subject to:

$x(t+1)=F(x(t),U(t)), \qquad U_{\min}\le U(t)\le U_{\max}$

This is the formal drug optimization engine.

XVI. FINAL SYNTHESIS

The engine does not ask:

“What symptom should be treated?”

It asks:

“What control vector best reduces chaos, restores current alignment, balances the axes, and moves this specific patient toward Stability with the least risk?”

That is the central SCF–CMF optimization logic.

MASTER REGISTRY INDEX

CMF-DOE-0011

CMF-STATE-ESTIMATOR-0012

CMF-CONTROL-VECTOR-0013

CMF-MPC-OPTIMIZER-0014

CMF-SAFETY-GOVERNOR-0015

CMF-STATE-SPECIFIC-CONTROL-0016

CMF-DIGITAL-TWIN-0017